Esperion Therapeutics (NASDAQ:ESPR) will release its earnings data before the market opens on Tuesday, February 20th. Analysts expect Esperion Therapeutics to post earnings of ($1.80) per share for the quarter.
Shares of Esperion Therapeutics (ESPR) opened at $68.22 on Tuesday. The company has a market cap of $1,750.00, a PE ratio of -9.94 and a beta of 2.64. Esperion Therapeutics has a 12-month low of $19.90 and a 12-month high of $82.18.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the transaction, the director now directly owns 2,472 shares of the company’s stock, valued at $133,117.20. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 32.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics (ESPR) to Release Earnings on Tuesday” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/13/esperion-therapeutics-espr-to-release-earnings-on-tuesday.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.